Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma

Muneer H. Abidi, Zartash Gul, Judith Abrams, Lois Ayash, Abhinav Deol, Marie Ventimiglia, Lawrence Lum, Stephanie Mellon-Reppen, Zaid Al-Kadhimi, Voravit Ratanatharathorn, Jeffrey Zonder, Joseph Uberti

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We enrolled 15 patients in this phase I dose de-escalation trial. Twelve patients are evaluable. The primary objective was to determine the safest and best tolerated maintenance dosing (MD) of bortezomib (B). The secondary endpoints were to evaluate complete response (CR), overall response (OR) and response duration. All patients receiving autologous stem cell transplant (ASCT) were eligible and registered between D+30 to D+120 after ASCT. A maximum number of 8 cycles of B was planned. Two evaluable patients in level (L) 1 received therapeutic dose of B 1.3 mg/m2 intravenously on days (D) 1, 4, 8, and 11 in a 21 day cycle. Both these patients experienced dose limiting toxicities (DLTs). Four evaluable patients were then enrolled in dose L2 utilizing B 1.3 mg/m2 on D 1, 4, 8, and 11 in a 28 day cycle. Two patients in L2 developed DLTs. Six evaluable patients were thereafter enrolled in L3 utilizing B 1 mg/m2 on D 1, 8, and 15 in a 28 day cycle. Median 8 cycles of B were administered (2-8). No DLTs were observed in L3. The median duration of follow up for the entire cohort is 33 months (12-62). The median duration of response in L3 is 29.1 months (12-33). We conclude that B 1 mg/m2 administered intravenously and may be subcutaneously on D 1, 8, and 15 in a 28 day cycle is the best tolerated MD and can be safely given beginning around D+100 post-ASCT.

Original languageEnglish (US)
Pages (from-to)167-172
Number of pages6
JournalJournal of Chemotherapy
Volume24
Issue number3
DOIs
StatePublished - Jun 1 2012

Fingerprint

Melphalan
Stem Cell Transplantation
Multiple Myeloma
Maintenance
Stem Cells
Transplants
Bortezomib

Keywords

  • Autologous stem cell transplantation
  • Bortezomib maintenance
  • Myeloma

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma. / Abidi, Muneer H.; Gul, Zartash; Abrams, Judith; Ayash, Lois; Deol, Abhinav; Ventimiglia, Marie; Lum, Lawrence; Mellon-Reppen, Stephanie; Al-Kadhimi, Zaid; Ratanatharathorn, Voravit; Zonder, Jeffrey; Uberti, Joseph.

In: Journal of Chemotherapy, Vol. 24, No. 3, 01.06.2012, p. 167-172.

Research output: Contribution to journalArticle

Abidi, MH, Gul, Z, Abrams, J, Ayash, L, Deol, A, Ventimiglia, M, Lum, L, Mellon-Reppen, S, Al-Kadhimi, Z, Ratanatharathorn, V, Zonder, J & Uberti, J 2012, 'Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma', Journal of Chemotherapy, vol. 24, no. 3, pp. 167-172. https://doi.org/10.1179/1973947812Y.0000000004
Abidi, Muneer H. ; Gul, Zartash ; Abrams, Judith ; Ayash, Lois ; Deol, Abhinav ; Ventimiglia, Marie ; Lum, Lawrence ; Mellon-Reppen, Stephanie ; Al-Kadhimi, Zaid ; Ratanatharathorn, Voravit ; Zonder, Jeffrey ; Uberti, Joseph. / Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma. In: Journal of Chemotherapy. 2012 ; Vol. 24, No. 3. pp. 167-172.
@article{03a8cc3678dc497ea3044a66706e0a0b,
title = "Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma",
abstract = "We enrolled 15 patients in this phase I dose de-escalation trial. Twelve patients are evaluable. The primary objective was to determine the safest and best tolerated maintenance dosing (MD) of bortezomib (B). The secondary endpoints were to evaluate complete response (CR), overall response (OR) and response duration. All patients receiving autologous stem cell transplant (ASCT) were eligible and registered between D+30 to D+120 after ASCT. A maximum number of 8 cycles of B was planned. Two evaluable patients in level (L) 1 received therapeutic dose of B 1.3 mg/m2 intravenously on days (D) 1, 4, 8, and 11 in a 21 day cycle. Both these patients experienced dose limiting toxicities (DLTs). Four evaluable patients were then enrolled in dose L2 utilizing B 1.3 mg/m2 on D 1, 4, 8, and 11 in a 28 day cycle. Two patients in L2 developed DLTs. Six evaluable patients were thereafter enrolled in L3 utilizing B 1 mg/m2 on D 1, 8, and 15 in a 28 day cycle. Median 8 cycles of B were administered (2-8). No DLTs were observed in L3. The median duration of follow up for the entire cohort is 33 months (12-62). The median duration of response in L3 is 29.1 months (12-33). We conclude that B 1 mg/m2 administered intravenously and may be subcutaneously on D 1, 8, and 15 in a 28 day cycle is the best tolerated MD and can be safely given beginning around D+100 post-ASCT.",
keywords = "Autologous stem cell transplantation, Bortezomib maintenance, Myeloma",
author = "Abidi, {Muneer H.} and Zartash Gul and Judith Abrams and Lois Ayash and Abhinav Deol and Marie Ventimiglia and Lawrence Lum and Stephanie Mellon-Reppen and Zaid Al-Kadhimi and Voravit Ratanatharathorn and Jeffrey Zonder and Joseph Uberti",
year = "2012",
month = "6",
day = "1",
doi = "10.1179/1973947812Y.0000000004",
language = "English (US)",
volume = "24",
pages = "167--172",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "3",

}

TY - JOUR

T1 - Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma

AU - Abidi, Muneer H.

AU - Gul, Zartash

AU - Abrams, Judith

AU - Ayash, Lois

AU - Deol, Abhinav

AU - Ventimiglia, Marie

AU - Lum, Lawrence

AU - Mellon-Reppen, Stephanie

AU - Al-Kadhimi, Zaid

AU - Ratanatharathorn, Voravit

AU - Zonder, Jeffrey

AU - Uberti, Joseph

PY - 2012/6/1

Y1 - 2012/6/1

N2 - We enrolled 15 patients in this phase I dose de-escalation trial. Twelve patients are evaluable. The primary objective was to determine the safest and best tolerated maintenance dosing (MD) of bortezomib (B). The secondary endpoints were to evaluate complete response (CR), overall response (OR) and response duration. All patients receiving autologous stem cell transplant (ASCT) were eligible and registered between D+30 to D+120 after ASCT. A maximum number of 8 cycles of B was planned. Two evaluable patients in level (L) 1 received therapeutic dose of B 1.3 mg/m2 intravenously on days (D) 1, 4, 8, and 11 in a 21 day cycle. Both these patients experienced dose limiting toxicities (DLTs). Four evaluable patients were then enrolled in dose L2 utilizing B 1.3 mg/m2 on D 1, 4, 8, and 11 in a 28 day cycle. Two patients in L2 developed DLTs. Six evaluable patients were thereafter enrolled in L3 utilizing B 1 mg/m2 on D 1, 8, and 15 in a 28 day cycle. Median 8 cycles of B were administered (2-8). No DLTs were observed in L3. The median duration of follow up for the entire cohort is 33 months (12-62). The median duration of response in L3 is 29.1 months (12-33). We conclude that B 1 mg/m2 administered intravenously and may be subcutaneously on D 1, 8, and 15 in a 28 day cycle is the best tolerated MD and can be safely given beginning around D+100 post-ASCT.

AB - We enrolled 15 patients in this phase I dose de-escalation trial. Twelve patients are evaluable. The primary objective was to determine the safest and best tolerated maintenance dosing (MD) of bortezomib (B). The secondary endpoints were to evaluate complete response (CR), overall response (OR) and response duration. All patients receiving autologous stem cell transplant (ASCT) were eligible and registered between D+30 to D+120 after ASCT. A maximum number of 8 cycles of B was planned. Two evaluable patients in level (L) 1 received therapeutic dose of B 1.3 mg/m2 intravenously on days (D) 1, 4, 8, and 11 in a 21 day cycle. Both these patients experienced dose limiting toxicities (DLTs). Four evaluable patients were then enrolled in dose L2 utilizing B 1.3 mg/m2 on D 1, 4, 8, and 11 in a 28 day cycle. Two patients in L2 developed DLTs. Six evaluable patients were thereafter enrolled in L3 utilizing B 1 mg/m2 on D 1, 8, and 15 in a 28 day cycle. Median 8 cycles of B were administered (2-8). No DLTs were observed in L3. The median duration of follow up for the entire cohort is 33 months (12-62). The median duration of response in L3 is 29.1 months (12-33). We conclude that B 1 mg/m2 administered intravenously and may be subcutaneously on D 1, 8, and 15 in a 28 day cycle is the best tolerated MD and can be safely given beginning around D+100 post-ASCT.

KW - Autologous stem cell transplantation

KW - Bortezomib maintenance

KW - Myeloma

UR - http://www.scopus.com/inward/record.url?scp=84866249683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866249683&partnerID=8YFLogxK

U2 - 10.1179/1973947812Y.0000000004

DO - 10.1179/1973947812Y.0000000004

M3 - Article

C2 - 22759762

AN - SCOPUS:84866249683

VL - 24

SP - 167

EP - 172

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 3

ER -